Corient Private Wealth LLC Sells 1,800 Shares of Balchem Co. (NASDAQ:BCPC)

Corient Private Wealth LLC lessened its holdings in shares of Balchem Co. (NASDAQ:BCPC) by 0.7% during the 4th quarter, Holdings Channel.com reports. The firm owned 254,192 shares of the basic materials company’s stock after selling 1,800 shares during the period. Corient Private Wealth LLC’s holdings in Balchem were worth $41,432,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Watts Gwilliam & Co. LLC grew its holdings in Balchem by 63.7% during the 4th quarter. Watts Gwilliam & Co. LLC now owns 35,069 shares of the basic materials company’s stock worth $5,438,000 after acquiring an additional 13,642 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Balchem by 1.7% in the third quarter. JPMorgan Chase & Co. now owns 458,986 shares of the basic materials company’s stock valued at $80,782,000 after purchasing an additional 7,721 shares in the last quarter. Stifel Financial Corp raised its position in Balchem by 26.2% in the 3rd quarter. Stifel Financial Corp now owns 11,893 shares of the basic materials company’s stock worth $2,093,000 after purchasing an additional 2,467 shares during the last quarter. Apollon Wealth Management LLC acquired a new position in Balchem during the 4th quarter worth $503,000. Finally, Congress Asset Management Co. boosted its position in Balchem by 5.4% in the 4th quarter. Congress Asset Management Co. now owns 317,610 shares of the basic materials company’s stock valued at $51,769,000 after buying an additional 16,170 shares during the last quarter. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on BCPC shares. Sidoti raised Balchem to a “hold” rating in a research note on Tuesday, February 25th. StockNews.com lowered shares of Balchem from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Finally, HC Wainwright reissued a “buy” rating and set a $190.00 price target on shares of Balchem in a research note on Monday, February 24th.

Balchem Stock Performance

BCPC stock opened at $168.46 on Tuesday. The company has a quick ratio of 1.16, a current ratio of 1.99 and a debt-to-equity ratio of 0.19. Balchem Co. has a twelve month low of $137.69 and a twelve month high of $186.03. The business’s fifty day moving average is $164.07 and its 200-day moving average is $169.70. The company has a market cap of $5.48 billion, a P/E ratio of 42.87, a price-to-earnings-growth ratio of 4.41 and a beta of 0.63.

Balchem (NASDAQ:BCPC) last released its earnings results on Friday, February 21st. The basic materials company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.11 by ($0.08). The company had revenue of $240.00 million during the quarter, compared to analyst estimates of $239.96 million. Balchem had a net margin of 13.47% and a return on equity of 11.37%. Equities research analysts forecast that Balchem Co. will post 4.64 EPS for the current year.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.